Daniel O’Day
Chairman and Chief Executive Officer
Mr. O’Day joined Gilead in March 2019 as Chairman of the Board of Directors and Chief Executive Officer. Prior to Gilead, Mr. O’Day served as the Chief Executive Officer of Roche Pharmaceuticals. His career at Roche spanned more than three decades, during which he held a number of executive positions in the company’s pharmaceutical and diagnostics divisions in North America, Europe and Asia. He served as a member of Roche’s Corporate Executive Committee, as well as on a number of public and private boards, including Genentech, Flatiron Health and Foundation Medicine. Mr. O’Day holds a bachelor’s degree in biology from Georgetown University and an MBA from Columbia University. He is currently the chair of the Board of Directors of the Pharmaceutical Research and Manufacturers of America (PhRMA) organization and he serves on the Board of Directors of Georgetown University.
-
Daniel O’Day
Chairman and Chief Executive Officer
-
Jacqueline K. Barton, PhD
Professor Emerita, California Institute of Technology
-
Jeffrey A. Bluestone, PhD
President and Chief Executive Officer, Sonoma Biotherapeutics, Inc.
-
Sandra J. Horning, MD
Retired Chief Medical Officer, Roche, Inc.
-
Kelly A. Kramer
Retired Chief Financial Officer, Cisco Systems, Inc.
-
Ted W. Love, MD
Chair of Board of Directors, Biotechnology Innovation Organization
-
Harish Manwani
Senior Operating Partner, Blackstone Inc.
-
Javier J. Rodriguez
Chief Executive Officer, DaVita Inc.
-
Anthony Welters
Lead Independent Director; Chairman and Chief Executive Officer, CINQ Care